Tarceva improves PFS 41% in advanced NSCLC
The USA's OSI Pharmaceuticals presented positive, detailed results from the Phase III SATURN study of Tarceva (erlotinib) as a single agent, first-line maintenance therapy for patients with advanced non-small cell lung cancer who did not progress following first-line treatment with platinum-based chemotherapy.
The study met both of its co-primary endpoints by demonstrating a statistically-significant 41% improvement in the time patients live without their disease worsening compared with placebo (p<0.00001) and a 45% increase in the time patients live without their disease worsening compared to control in the sub-set of patients who were determined to have tumors expressing the EGFR gene by Immunohistochemistry (p<0.0001).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze